NAA Services for Anti-Peroxiredoxin VI

Elevated levels of anti-peroxiredoxin VI (PRDX6) have been described in several cancers including gastric cancer (GC). Early detection and efficient monitoring of tumor dynamics are prerequisites for reducing disease burden and mortality, and for improving the management of patients with GC. As a long-term expert in disease early detection, Creative Biolabs owns lots of scientists who are proficient in the establishment of natural autoantibody (NAA) detection methods. Our professional scientists are pleased to provide the custom anti-PRDX6 services to promote your project.

Background of Peroxiredoxin VI

Peroxiredoxins (PRDXs) are a ubiquitously expressed family of small (22-27 kDa) non-seleno peroxidases that catalyze the peroxide reduction of H2O2, organic hydroperoxides, and peroxynitrite. PRDXs are composed of six enzymes. PRDX1-5 have two reactive cysteines and they use thioredoxin and/or glutathione as a substrate. By contrast, PRDX6 has important and unique characteristics. It has a single conserved Cys residue causing a different catalytic cycle, and it uses glutathione (GSH) instead of thioredoxin as the physiological reductant. PRDX6 has been reported to be implicated in the development and progression of cancers. For example, elevated expression levels of PRDX6 have been associated with a more invasive phenotype and metastatic potential of breast cancer, and with a worse prognosis of clinically localized prostate cancer following radical prostatectomy.

Schematic representation of the role of PRDX6 in the ROS-mediated interplay between inflammatory cells and endothelial cells. Fig.1 Schematic representation of the role of PRDX6 in the ROS-mediated interplay between inflammatory cells and endothelial cells. (Kümin, 2007)

The Role of Anti-peroxiredoxin VI in Gastric Cancer

GC is a multifactorial disease, and both genetic and environmental factors have a role in its etiology. The 5-year survival rate of early diagnosed GC patients is higher than 90%, while it is only 30-40% for advanced GC. Blood-based biomarker assays are of great importance for the detection of early-stage GC. Expression of PRDX6 is markedly higher in tumor tissue than in normal epithelium and dysplastic lesion at the protein level according to immunohistochemistry. The detection of autoantibody against PRDX6 may serve not only to diagnose NPC but also to develop new targeted therapies according to the current publications.

Signaling pathway related to cancer development. Fig.2 Signaling pathway related to cancer development. (Park, 2016)

What We Can Do About NAA?

Equipped with our well-established platforms and experienced scientists, we can provide comprehensive NAA services, from NAA detection, NAA profiling, to NAA epitope mapping. A wide spectrum of NAA products is available for your choice.

Features of Our Services

Current status arouses researcher’s interest in cancer early diagnosis by single or panel of autoantibodies against multiple tumor-associated antigens. With years of experience in the field of disease diagnosis and NAA detection, Creative Biolabs is capable of providing a great variety of services against different markers including but not limited to PRDX6 for the diagnosis of GC. Moreover, we provide customized solutions to meet the requirements of every client. Please feel free to contact us for more information and a formal quote.

References:

  1. Kümin, A.; et al. Peroxiredoxin 6 is required for blood vessel integrity in wounded skin. The Journal of cell biology. 2007, 179(4): 747-760.
  2. Park, M.H.; et al. Roles of peroxiredoxins in cancer, neurodegenerative diseases and inflammatory diseases. Pharmacology & therapeutics. 2016, 163: 1-23.
For Research Use Only | Not For Clinical Use

Related Services:

Products:

Resource:

Applications:

Online Inquiry
Inquiry